Carvedilol and rosuvastatin mitigate nephrotoxicity of sodium valproate through activation of Nrf2 pathway in rats.
Abd El-Fattah, N., Eid, A., Zaky, H., Ahmed, H. (2021). Carvedilol and rosuvastatin mitigate nephrotoxicity of sodium valproate through activation of Nrf2 pathway in rats.. EKB Journal Management System, 1(3), 9-20. doi: 10.21608/aijpms.2021.206679
Nourhan Abd El-Fattah; Ahmed Eid; Heba Zaky; Hebatalla Ahmed. "Carvedilol and rosuvastatin mitigate nephrotoxicity of sodium valproate through activation of Nrf2 pathway in rats.". EKB Journal Management System, 1, 3, 2021, 9-20. doi: 10.21608/aijpms.2021.206679
Abd El-Fattah, N., Eid, A., Zaky, H., Ahmed, H. (2021). 'Carvedilol and rosuvastatin mitigate nephrotoxicity of sodium valproate through activation of Nrf2 pathway in rats.', EKB Journal Management System, 1(3), pp. 9-20. doi: 10.21608/aijpms.2021.206679
Abd El-Fattah, N., Eid, A., Zaky, H., Ahmed, H. Carvedilol and rosuvastatin mitigate nephrotoxicity of sodium valproate through activation of Nrf2 pathway in rats.. EKB Journal Management System, 2021; 1(3): 9-20. doi: 10.21608/aijpms.2021.206679

Carvedilol and rosuvastatin mitigate nephrotoxicity of sodium valproate through activation of Nrf2 pathway in rats.

Azhar International Journal of Pharmaceutical and Medical Sciences
Article 2, Volume 1, Issue 3, November 2021, Page 9-20  XML PDF (1019.84 K)
Document Type: Original research articles
DOI: 10.21608/aijpms.2021.206679
View on SCiNiTO View on SCiNiTO
Authors
Nourhan Abd El-Fattah1; Ahmed Eid1; Heba Zaky email orcid 2; Hebatalla Ahmedorcid 2
1Department of Pharmacology, Egyptian Drug Authority (EDA),formerly NODCAR,Giza, Egypt.
2Department of Pharmacology and Toxicology, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt.
Abstract
Sodium valproate, one of the most widely used antiepileptic drugs, has been noted to induce nephrotoxicity through elevation of oxidative stress. Carvedilol, a non-specific beta-adrenergic blocker, and rosuvastatin, an anti-hyperlipidemic, possess antioxidant characteristics. This study was planned to estimate the promising defensive impacts of Carvedilol and/or rosuvastatin against valproate‐induced nephrotoxicity. It was revealed that sodium valproate (SVP) markedly boosted serum creatinine (SCr) and blood urea nitrogen (BUN). Moreover, glutathione level (GSH) was decreased with a concomitant elevation in renal malondialdehyde level (MDA) and inducible nitric oxide synthase activities (iNOS). After SVP treatment, there were significant elevations in renal tumor necrosis factor‐alpha (TNF-𝛼) and nuclear factor‐kappa B (NF‐κB). Additionally, SVP‐induced suppression of nuclear related factor 2 (Nrf2) pathways. Furthermore, histopathological examination showed prodigious inflammation, necrosis, congestion and degeneration. Coadministration of Carvedilol and/or rosuvastatin mitigated nephrotoxicity induced by SVP. Using the combination of Carvedilol and rosuvastatin presented additional intense renal protective effect when compared with each alone.
Keywords
Carvedilol; Rosuvastatin; Sodium valproate; Nrf2 pathway; Nephroprotection
Statistics
Article View: 399
PDF Download: 288